AndroGel and Rivaroxaban Interaction: What Patients and Clinicians Need to Know

HealthRX.com

No documented AndroGel and rivaroxaban interaction found

Print or save as PDF

Key numbers

  • 3.0%Mean hematocrit rise with testosterone gel vs placebo across 29 randomized trials in 3,393 menSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 4.0%Mean hematocrit rise with intramuscular enanthate or cypionate vs placebo across 29 randomized trials in 3,393 menSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 1.7% versus 1.2%VTE in TRAVERSE: 1.7% with daily 1.62% gel vs 1.2% with placebo gelSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

From the public record

FDA adverse event reports listing both rivaroxaban and testosterone

Through 2026-10-28, FDA had received 446 adverse event reports that list both rivaroxaban and testosterone, out of 193,780 reports for rivaroxaban and 41,579 for testosterone. A joint report shows both were recorded for the same person, not that they interacted.

FDA adverse event reports listing both rivaroxaban and testosterone: the figures
MeasureValue
Reports listing both drugs446
All reports for rivaroxaban193,780
All reports for testosterone41,579
Joint reports naming fatigue30
Joint reports naming diarrhoea24
Joint reports naming gastrointestinal haemorrhage23
Joint reports naming pulmonary embolism21

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, data as of Oct 28, 2026

How this was calculated

Counted FAERS reports that list both active substances in any role, then the symptom terms named most often in those reports. Terms about product use rather than symptoms were left out. The events may relate to either drug, to another drug, or to the illness.

Scope: Reports listing both rivaroxaban and testosterone as single-ingredient active substances, any brand, suspect or concomitant

FAERS reports are unverified and do not prove the drug caused the event. Reporting rises with use, publicity and lawsuits, so these counts cannot give rates or risks and cannot be compared between drugs. Joint reports are not evidence of an interaction.

Download the data (CSV)

From the public record

Published papers mentioning both testosterone and rivaroxaban

PubMed indexes 7 papers whose title or abstract mentions both testosterone and rivaroxaban, 6 of them published from 2016 to 2025. For comparison, 103,536 papers mention testosterone and 9,513 mention rivaroxaban.

Published papers mentioning both testosterone and rivaroxaban: the figures
MeasureValue
Papers mentioning both7
Of those, published 2016 to 20256
Papers mentioning testosterone103,536
Papers mentioning rivaroxaban9,513

Source: NIH National Library of Medicine, PubMed, data as of Nov 11, 2026

How this was calculated

Ran one PubMed title and abstract search requiring both names, and one search for each name alone. No filtering by study type or quality.

Scope: PubMed records naming both substances in the title or abstract, all article types and species

A paper that mentions both is not necessarily a study of their interaction, and may report no interaction. Counts include animal, cell and review papers.

Download the data (CSV)

At a glance

  • Rivaroxaban class / Direct factor Xa inhibitor, an oral anticoagulant (not a vitamin K antagonist) [4]
  • Anticoagulant entry, generic 1.62% gel label / Androgens may change anticoagulant activity; more frequent INR and prothrombin-time monitoring recommended; no anticoagulant named [1]
  • Xarelto label on monitoring / Monitoring its anticoagulant effect with PT, INR, aPTT or anti-factor Xa tests is not recommended [4]
  • Hematocrit checks, generic 1.62% gel label / Before treatment, 3 to 6 months after starting, then annually [1]
  • Mean hematocrit rise with gel / 3.0% vs placebo across 29 randomized trials, 3,393 men [2]
  • VTE in TRAVERSE, 1.62% gel vs placebo / 1.7% vs 1.2% [1]

What the testosterone gel label says about anticoagulants

AndroGel is a topical testosterone gel, and 1.62% is one of its strengths. The label text discussed on this page is a generic 1.62% testosterone gel label, not AndroGel's own label. Its drug interactions section lists insulin, oral anticoagulants and corticosteroids. The anticoagulant entry says changes in anticoagulant activity may be seen with androgens, so more frequent monitoring of international normalized ratio (INR) and prothrombin time is recommended in patients taking anticoagulants, especially at the start and end of androgen therapy [1]. The entry names no specific anticoagulant [1].

Questions worth asking

Choose the questions you want to keep

What the Xarelto label says

Rivaroxaban inhibits factor Xa. It is cleared by CYP3A4/5 and CYP2J2 metabolism plus P-glycoprotein and BCRP transport [4]. The Xarelto label says it can cause serious and fatal bleeding, and that aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs raise bleeding risk. It also says monitoring the anticoagulant effect with PT, INR, aPTT or anti-factor Xa tests is not recommended [4]. The INR and prothrombin-time advice in the testosterone gel label is therefore written generally for anticoagulants, and the Xarelto label does not use those tests to follow rivaroxaban.

Hematocrit: what the generic gel label asks for and how big the effect is

The polycythemia section of the generic 1.62% gel label says to check hematocrit before starting treatment, re-evaluate it 3 to 6 months after starting, and then check it annually. It says that if hematocrit becomes elevated, therapy should be stopped until it decreases to an acceptable concentration, and that an increase in red blood cell mass may increase the risk of thromboembolic events [1]. It describes an acceptable concentration rather than a specific number [1].

The average change is modest but real. A network meta-analysis of 29 placebo-controlled randomized trials in 3,393 men found that testosterone gel raised mean hematocrit by 3.0% versus placebo (95% CI 1.8 to 4.3), and intramuscular enanthate or cypionate raised it by 4.0% (95% CI 2.9 to 5.1) [2].

Venous thromboembolism appears separately in that label. It notes postmarketing reports of deep vein thrombosis and pulmonary embolism with testosterone products. In TRAVERSE, which randomized 5,246 men to daily 1.62% gel or placebo gel [3], VTE occurred in 1.7% versus 1.2%, DVT in 0.6% versus 0.5%, and PE in 0.9% versus 0.5% [1].

What the generic gel label says to watch for

That label says pain, edema, warmth and erythema in the lower extremity should prompt evaluation for DVT, and acute shortness of breath should prompt evaluation for PE. If a venous thromboembolic event is suspected, the label directs discontinuation of the gel and appropriate workup [1].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. What does the Xarelto label say about monitoring rivaroxaban's anticoagulant effect with PT, INR, aPTT or anti-factor Xa tests?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Frequently asked questions

Can I take AndroGel with rivaroxaban?
No study of the pair was located. A generic 1.62% testosterone gel label warns that androgens may change anticoagulant activity and recommends more frequent INR and prothrombin-time monitoring in patients taking anticoagulants, but it does not name rivaroxaban [1].
Does rivaroxaban need INR checks?
The Xarelto label says monitoring its anticoagulant effect with PT, INR, aPTT or anti-factor Xa tests is not recommended [4].
How often does the gel label say hematocrit should be checked?
The generic 1.62% gel label says to check it before treatment, again 3 to 6 months after starting, and then annually. It says to stop therapy if it becomes elevated until it falls to an acceptable concentration [1].
Does the gel label name rivaroxaban?
No. The anticoagulant entry is general, covering anticoagulants as a class without naming rivaroxaban or any other product [1].
How much does testosterone gel raise hematocrit?
Across 29 placebo-controlled randomized trials in 3,393 men, gel raised mean hematocrit by 3.0% versus placebo (95% CI 1.8 to 4.3) [2].
What clot symptoms does the gel label describe?
Pain, edema, warmth and erythema in the lower extremity for DVT and acute shortness of breath for PE. If a venous thromboembolic event is suspected, the label directs stopping the gel and starting workup [1].

References

Show all 4 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Testosterone gel 1.62% topical, generic (Padagis), the AndroGel 1.62% formulation type prescribing information. Testosterone gel 1.62% topical, generic (Padagis), the AndroGel 1.62% formulation type label
  2. Nackeeran S, Kohn T, Gonzalez D, White J, Ory J, Ramasamy R. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials. J Urol. 2022;207(1):44-51.
  3. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117.
  4. U.S. Food and Drug Administration. Xarelto (rivaroxaban) prescribing information, label effective 2026-09-10. Drugs@FDA: FDA-Approved Drugs
Evidence overview for AndroGel and Rivaroxaban Interaction: What Patients and Clinicians Need to Know